3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Cisplatin
6
Platinum
5
Pemetrexed
5
1,2-diaminocyclohexaneplatinum II citrate
5
pembrolizumab
4
atezolizumab
2
Radiotherapy
2
Radiation
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
tremelimumab
1
methoxyamine
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cediranib
1
anetumab ravtansine
1
aldesleukin
1
Trioxsalen
1
Tissue Banks
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Phototherapy
1
Photochemotherapy
1
Pharmacogenomic Testing
1
Pharmaceutical Preparations
1
Interleukin-2
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.